Literature DB >> 29249606

Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.

Jie Li1, Daniel Watterson2, Chiung-Wen Chang3, Xiao-Yan Che4, Xiao-Quan Li4, Daniel J Ericsson5, Li-Wen Qiu4, Jian-Piao Cai4, Jing Chen4, Scott R Fry6, Stacey T M Cheung3, Matthew A Cooper7, Paul R Young8, Bostjan Kobe9.   

Abstract

Understanding the molecular basis of the neutralizing antibody response to dengue virus (DENV) is an essential component in the design and development of effective vaccines and immunotherapeutics. Here we present the structure of a cross-reactive, neutralizing antibody, 3E31, in complex with domain III (DIII) of the DENV envelope (E) protein and reveal a conserved, temperature-sensitive, cryptic epitope on DIII that is not available in any of the known conformations of E on the dengue virion. We observed that 3E31 inhibits E-mediated membrane fusion, suggesting that the antibody is able to neutralize virus through binding an as-yet uncharacterized intermediate conformation of DENV E and sterically block trimer formation. Finally, we show that, unlike cross-reactive fusion peptide-specific antibodies, 3E31 does not promote antibody-dependent enhancement of infection at sub-neutralizing concentrations. Our results highlight the 3E31 epitope on the E protein DIII as a promising target for immunotherapeutics or vaccine design.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antibody-dependent enhancement; cross-reactive; cryptic epitope; dengue; membrane fusion; neutralizing antibody; temperature sensitive

Mesh:

Substances:

Year:  2017        PMID: 29249606     DOI: 10.1016/j.str.2017.11.017

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  15 in total

Review 1.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

2.  Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.

Authors:  Ellen Young; Robert H Carnahan; Daniela V Andrade; Nurgun Kose; Rachel S Nargi; Ethan J Fritch; Jennifer E Munt; Michael P Doyle; Laura White; Thomas J Baric; Mark Stoops; Aravinda DeSilva; Longping V Tse; David R Martinez; Deanna Zhu; Stefan Metz; Marcus P Wong; Diego A Espinosa; Magelda Montoya; Scott B Biering; Soila Sukulpolvi-Petty; Guillermina Kuan; Angel Balmaseda; Michael S Diamond; Eva Harris; James E Crowe; Ralph S Baric
Journal:  Cell Host Microbe       Date:  2020-05-13       Impact factor: 21.023

3.  Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins.

Authors:  Stephan T Kudlacek; Lakshmanane Premkumar; Stefan W Metz; Ashutosh Tripathy; Andrey A Bobkov; Alexander Matthew Payne; Stephen Graham; James A Brackbill; Michael J Miley; Aravinda M de Silva; Brian Kuhlman
Journal:  J Biol Chem       Date:  2018-04-20       Impact factor: 5.157

4.  Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.

Authors:  Max Renner; Aleksandra Flanagan; Wanwisa Dejnirattisai; Chunya Puttikhunt; Watchara Kasinrerk; Piyada Supasa; Wiyada Wongwiwat; Kriangkrai Chawansuntati; Thaneeya Duangchinda; Alison Cowper; Claire M Midgley; Prida Malasit; Juha T Huiskonen; Juthathip Mongkolsapaya; Gavin R Screaton; Jonathan M Grimes
Journal:  Nat Immunol       Date:  2018-10-15       Impact factor: 25.606

5.  Flavivirus Entry Inhibitors.

Authors:  Yufeng Yu; Lulu Si; Yu Meng
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Antibodies to Cryptic Epitopes in Distant Homologues Underpin a Mechanism of Heterologous Immunity between Plasmodium vivax PvDBP and Plasmodium falciparum VAR2CSA.

Authors:  Catherine J Mitran; Angie Mena; Sedami Gnidehou; Shanna Banman; Eliana Arango; Barbara A S Lima; Hazel Lugo; Aravindhan Ganesan; Ali Salanti; Anthony K Mbonye; Francis Ntumngia; Khaled Barakat; John H Adams; Flora S Kano; Luzia H Carvalho; Amanda E Maestre; Michael F Good; Stephanie K Yanow
Journal:  mBio       Date:  2019-10-08       Impact factor: 7.867

7.  An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2.

Authors:  Alberto A Amarilla; Naphak Modhiran; Yin Xiang Setoh; Nias Y G Peng; Julian D J Sng; Benjamin Liang; Christopher L D McMillan; Morgan E Freney; Stacey T M Cheung; Keith J Chappell; Alexander A Khromykh; Paul R Young; Daniel Watterson
Journal:  Front Microbiol       Date:  2021-02-12       Impact factor: 5.640

Review 8.  Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?

Authors:  Lucas Wilken; Guus F Rimmelzwaan
Journal:  Pathogens       Date:  2020-06-15

9.  Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.

Authors:  Haiyan Zhao; Lily Xu; Robin Bombardi; Rachel Nargi; Zengqin Deng; John M Errico; Christopher A Nelson; Kimberly A Dowd; Theodore C Pierson; James E Crowe; Michael S Diamond; Daved H Fremont
Journal:  J Exp Med       Date:  2020-02-03       Impact factor: 14.307

10.  Efficient Delivery of Dengue Virus Subunit Vaccines to the Skin by Microprojection Arrays.

Authors:  David A Muller; Alexandra C I Depelsenaire; Ashleigh E Shannon; Daniel Watterson; Simon R Corrie; Nick S Owens; Christiana Agyei-Yeboah; Stacey T M Cheung; Jin Zhang; Germain J P Fernando; Mark A F Kendall; Paul R Young
Journal:  Vaccines (Basel)       Date:  2019-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.